Introduction
Gastric cancer, death, gastrooesophageal junction cancer, cancer, cancer death, advanced/metastatic, GEJC
GASTRIC CANCER, GASTROOESOPHAGEAL JUNCTION CANCER, CANCER
Gastric cancer (GC) and gastrooesophageal junction cancer (GEJC) is the fifth most frequently diagnosed cancer and the third leading cause of cancer death globally (The standard of care for the 85% of patients with unresectable, locally advanced/metastatic GC/GEJC in Asia is doublet or triplet fluoropyrimidine- and platinum-based chemotherapy in the first-line treatment setting (The anti–programmed death 1 (PD-1) monoclonal antibody pembrolizumab first demonstrated antitumour activity in previously untreated and treated patients with GC/GEJC in the multicohort phase 2 KEYNOTE-059 study (Given the differences in median OS and in regional use of second-line chemotherapy, we conducted a post hoc subgroup analysis to further describe the efficacy and safety of pembrolizumab (with or without chemotherapy) compared with chemotherapy alone in patients with GC/GEJC who were enrolled in Asia in the KEYNOTE-062 study.